These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 18445854)

  • 1. Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer.
    Chu E; Cartwright TH
    J Clin Oncol; 2008 May; 26(13):2224-6; author reply 2228. PubMed ID: 18445854
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
    Cassidy J; Schmoll HJ; Van Cutsem E
    J Clin Oncol; 2008 May; 26(13):2226-7; author reply 2228. PubMed ID: 18445855
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
    Hsu TC; Chen HH; Yang MC; Wang HM; Chuang JH; Jao SW; Chiang HC; Wen CY; Tseng JH; Chen LT
    Value Health; 2011; 14(5):647-51. PubMed ID: 21839401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
    Chu E; Schulman KL; McKenna EF; Cartwright T
    Clin Colorectal Cancer; 2010 Oct; 9(4):229-37. PubMed ID: 20920995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
    Tran G; Hack SP; Kerr A; Stokes L; Gibbs P; Price T; Todd C
    Asia Pac J Clin Oncol; 2013 Sep; 9(3):239-48. PubMed ID: 23279720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer.
    Camacho FT; Wu J; Wei W; Kimmick G; Anderson RT; Balkrishnan R
    J Med Econ; 2009 Sep; 12(3):238-45. PubMed ID: 19732030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health economic analysis of fluoropyrimidine-based therapies of colorectal cancer from the perspective of statutory sickness funds.
    Grothey A; Kleeberg UR; Stauch M; Hieke K
    Z Gastroenterol; 2005 Feb; 43(2):155-61. PubMed ID: 15700205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Con: Pumpin' FU (or, avoiding that oral fixation).
    Hochster HS
    Clin Adv Hematol Oncol; 2005 May; 3(5):405-6. PubMed ID: 16167014
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6.
    Perrocheau G; Bennouna J; Ducreux M; Hebbar M; Ychou M; Lledo G; Conroy T; Dominguez S; Faroux R; Florentin V; Douillard JY
    Oncology; 2010; 79(3-4):174-80. PubMed ID: 21358204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XELOX in colorectal cancer: a convenient option for the future?
    Lindsay CR; Cassidy J
    Expert Rev Gastroenterol Hepatol; 2011 Feb; 5(1):9-19. PubMed ID: 21309667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NICE rejects drug for metastatic breast cancer because of cost and poor efficacy.
    Pownall M
    BMJ; 2010 Jun; 340():c3145. PubMed ID: 20543014
    [No Abstract]   [Full Text] [Related]  

  • 12. The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study.
    Carter HE; Zannino D; John Simes R; Schofield DJ; Howard K; Zalcberg JR; Price TJ; Tebbutt NC
    Eur J Cancer; 2014 Feb; 50(3):535-43. PubMed ID: 24215848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer.
    Best JH; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):103-14. PubMed ID: 20384557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
    Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
    Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients.
    De Portu S; Mantovani LG; Ravaioli A; Tamburini E; Bollina R; Cozzi C; Grimaldi AM; Testa TE; Bianchessi C; Carteni G
    J Chemother; 2010 Apr; 22(2):125-8. PubMed ID: 20435573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CAP-CR study: direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine.
    Lopatriello S; Amoroso D; Donati S; Alabiso O; Forti L; Fornasiero A; Smergo A; Lalli A; Iacono C; Lucenti A; D'Alonzo L; Negrini C
    Eur J Cancer; 2008 Nov; 44(17):2615-22. PubMed ID: 18805000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer.
    Almond J; Ralston S
    Br J Cancer; 2007 May; 96(9):1489; author reply 1490. PubMed ID: 17437019
    [No Abstract]   [Full Text] [Related]  

  • 18. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.
    Whyte S; Pandor A; Stevenson M; Rees A
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):47-53. PubMed ID: 21047491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence.
    Comella P; Casaretti R; Sandomenico C; Avallone A; Franco L
    Drugs; 2008; 68(7):949-61. PubMed ID: 18457461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of mortality and costs associated with FOLFOX versus FOLFIRI in stage IV colorectal cancer.
    Nelson MA; Shetty S; Kulakodlu M; Harley C; Seal B
    J Med Econ; 2011; 14(2):179-86. PubMed ID: 21319948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.